With reports of Alex Bregman signing a three-year deal with the Red Sox, Thursday is a great day for Boston baseball.

A $30,000 scholarship programme will be launched alongside internship opportunities for science graduates as Roche Bermuda ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

The public sector is operating with an outdated model and the system is no longer fit for purpose, according to Public ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...